English
Language31 languages
EnglishEnglishDeutschGermanالعربيةArabicFrançaisFrenchEspañolSpanishPortuguês (Brasil)Brazilian PortugueseItalianoItalian日本語Japanese한국어KoreanРусскийRussianTürkçeTurkishفارسیPersian (Farsi)עבריתHebrewҚазақшаKazakhPolskiPolishNederlandsDutchRomânăRomanianČeštinaCzechΕλληνικάGreekMagyarHungarianBahasa IndonesiaIndonesianहिन्दीHindiاردوUrduBahasa MelayuMalayไทยThaiУкраїнськаUkrainianO‘zbekchaUzbekTiếng ViệtVietnamese繁體中文Traditional ChineseDanskDanishSvenskaSwedish

Supported languages are prioritized from the country mix of past inquiries. If you would like another language, please send us feedback.

Recent Confirmed OrdersLast 7 days
United States220 mgMelanotan II 10 mg · TB-500 2 mg · Bacteriostatic Water 10 ml
View all

Repair and regenerative research

GHK-Cu

Copper(II)-complexed GHK tripeptide · supplied form and copper stoichiometry are procurement-critical

Lot-specific released result; require chromatography, quantitative peptide content or assay, copper content and orthogonal identity · target, verify batch COACAS 89030-95-5RUO
Research statusExtensive cell and animal literature; limited formulation-specific human evidence; exact supplied form must be qualified
Supplied formCopper(II)-coordinated Gly-His-Lys tripeptide complex
Lead timeConfirmed with quote
GHK-Cu — Lot-specific lyophilized solid; confirm colour, physical form and copper basis on the released-lot COA
GHK-Cu — Lot-specific lyophilized solid; confirm colour, physical form and copper basis on the released-lot COA · Representative packaging image · verify the ordered lot
Representative packaging image · verify the ordered lot

Decision summary

Key benefits

  • Research applications include copper–peptide coordination and stoichiometry, analytical identity and impurity methods, fibroblast and extracellular-matrix models, wound-model research, formulation stability and properly substantiated cosmetic-ingredient evaluation
  • Cosmetic or preclinical observations are not proof of injectable, wound-healing, hair-growth or anti-ageing efficacy.
Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS
89030-95-5
Formula
C14H24CuN6O4 for PubChem CID 378611 or C14H23CuN6O4⁺ for CID 71587328; confirm the supplied form
Molecular weight
403.92 Da
Appearance
Lot-specific lyophilized solid; confirm colour, physical form and copper basis on the released-lot COA
Purity
Lot-specific released result; require chromatography, quantitative peptide content or assay, copper content and orthogonal identity · target, verify batch COA
Storage
Follow the released-lot COA, SDS and lot-specific stability statement. Copper complexation, salt form, excipients, concentration, matrix, container and light exposure can change stability; do not copy a finished cosmetic shelf life or generic post-reconstitution period to this lot.
MOQ
On request
Lead time
Confirmed with quote

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about GHK-Cu

GHK-Cu is a copper(II) complex of the Gly-His-Lys tripeptide. Reviews describe extensive cell and animal work on extracellular-matrix, wound and gene-expression models, while human evidence is concentrated in specific topical formulations and is more limited than marketing summaries imply. PubChem CID 378611 is a neutral Cu-GHK representation and CID 71587328 is a cationic prezatide-copper representation; free GHK CID 73587 and acetate-associated CID 154723978 are different records. Copper Tripeptide-1 is an INCI ingredient name, not FDA approval. FDA states that compounded injectable GHK-Cu may pose immunogenicity risk from aggregation and peptide-related impurities and that human safety data are limited.

  • Copper-complex identity and stoichiometry; analytical and stability method development; controlled fibroblast, extracellular-matrix, wound, inflammatory and angiogenesis models; and cosmetic-formulation research with substantiated claims
  • These are research applications, not clinical indications.

Mechanism context

The question the literature is testing

GHK coordinates copper(II) through donor atoms in the tripeptide and is studied as a copper-delivery and signalling complex. Cell and animal models report changes in fibroblast activity, extracellular-matrix synthesis and remodelling, metalloproteinase balance, inflammatory signalling and angiogenesis-related endpoints. Results depend on chemical form, copper stoichiometry, model, formulation, concentration and delivery context and do not establish clinical efficacy or injectable safety.

Evidence map

Research routes and exposure context

Evidence tierMixed evidence context
Routes reported in sources
Topical
Dose / exposure contextProtocol-specific; verify the cited primary source
Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

  • Not for injection or other human or veterinary administration
  • FDA states that compounded injectable GHK-Cu may pose immunogenicity risk because of potential aggregation and peptide-related impurities and that human data are limited for safety assessment
  • For cosmetic R&D, the CIR conclusion applies only to the cosmetic practices and concentrations assessed; ingredient-level information does not establish finished-product safety
  • Irritation, sensitisation, microbiological quality, stability, exposure and claims require formulation-specific assessment under applicable law
  • Follow the SDS and institutional controls.

Interactions reported in the literature

  • No general compatibility or drug-interaction guidance applies
  • Stability and compatibility with acids, reducing agents, chelators, oxidants, other peptides, preservatives or packaging must be tested in the exact formulation; vendor pairings with BPC-157, TB-500 or CJC-1295 are not evidence.
Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

GHK-Cu factory batch COAs

GHK-Cu 50 mg Factory batch COA protected previewGHK-Cu50 mg · WHJLP-CU50-260318-C
GHK-Cu 100 mg Factory batch COA protected previewGHK-Cu100 mg · WHJLP-CU100-260318-C
Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

  • Require exact peptide and copper-complex identity, charge/salt convention, theoretical and observed intact mass, orthogonal peptide identity, quantitative peptide content, copper assay and stoichiometry, stability-indicating HPLC purity and impurity profile, water/counterion/residual solvents and lot-specific stability
  • Microbial limits, preservative effectiveness and finished-product compatibility are separate tests
  • Colour or clarity alone is not a release test.
Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack
GHKCU-050MG50 mg10 vials
GHKCU-100MG100 mg10 vials

Handling

Storage in the lab and temperature during transit are different decisions

Follow the released-lot COA, SDS and lot-specific stability statement. Copper complexation, salt form, excipients, concentration, matrix, container and light exposure can change stability; do not copy a finished cosmetic shelf life or generic post-reconstitution period to this lot.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls
These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

  • Identity: NIH PubChem CIDs 378611, 71587328, 73587 and 154723978, which distinguish neutral Cu-GHK, cationic prezatide copper, free GHK and an acetate-associated record. Scientific context: PMID 29986520 / PMCID PMC6073405, PMCID PMC4508379, PMCID PMC4180391 and the foundational 1980 Nature copper-uptake paper. Cosmetic context: CIR's final Tripeptide-1 safety assessment, limited to the practices and concentrations reviewed. Regulatory context: current FDA cosmetics guidance and FDA's injectable-GHK-Cu entry among withdrawn bulk-substance nominations that may present significant safety risks. Each study and order must retain its exact chemical form and formulation.
  1. 01

    Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver

    Nature New Biology · 1973 · peer-reviewed original research (landmark discovery paper)

    Open source
  2. 02

    Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+

    FEBS Letters · 1988 · peer-reviewed original research (landmark mechanism paper)

    Open source
  3. 03

    The Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Aging: Implications for Cognitive Health

    Oxidative Medicine and Cellular Longevity · 2012 · peer-reviewed review article

    Open source
  4. 04

    Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data

    International Journal of Molecular Sciences · 2018 · peer-reviewed review article

    Open source
  5. 05

    The potential of GHK as an anti-aging peptide

    Aging Pathobiology and Therapeutics · 2020 · peer-reviewed review article

    Open source
  6. 06

    Effects of GHK-Cu on MMP and TIMP Expression, Collagen and Elastin Production, and Facial Wrinkle Parameters

    Journal of Aging Science · 2016 · original report (in vitro work plus a small topical comparison; journal quality and independent replication limitations apply)

    Open source
  7. 07

    Safety Assessment of Tripeptide-1, Hexapeptide-12, Their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in Cosmetics

    International Journal of Toxicology (published on behalf of the Cosmetic Ingredient Review Expert Panel) · 2018 · Cosmetic Ingredient Review expert-panel safety assessment (cosmetic-use context; not FDA approval)

    Open source
  8. 08

    Epigenetic mechanisms activated by GHK-Cu increase skin collagen density in clinical trial

    EurekAlert! (AAAS-operated science news release platform); Yuvan Research Inc. · 2023 · company press release / clinical study announcement

    Open source

Product FAQ

Questions buyers ask about GHK-Cu

Which GHK-Cu identity fields must be fixed in an order?+

Specify GHK-Cu versus free GHK, neutral versus cationic representation, free base versus acetate-associated material, exact CAS/CID convention, counterion, formula and theoretical mass basis. Confirm peptide identity by intact mass or another orthogonal method and measure copper content or stoichiometry. Colour, INCI name and catalogue name are not identity tests.

Why are HPLC area purity and copper colour insufficient?+

RP-HPLC area describes peak distribution under one method; it does not quantify net peptide, copper, water, counterions or residual solvents. Blue colour can be consistent with a copper complex but cannot establish sequence, stoichiometry, purity, stability or microbial quality. A defensible COA separates chromatographic purity from quantitative assay and includes orthogonal identity and copper measurement.

What does Copper Tripeptide-1 mean in cosmetic work?+

Copper Tripeptide-1 is an INCI ingredient name, not FDA approval. FDA states that cosmetics and ingredients generally do not undergo premarket approval except for colour additives. The formulator remains responsible for finished-product safety, claims, labelling, stability and destination-market compliance. Injectable GHK-Cu is not an FDA-approved drug.

Related research materials

Compare adjacent molecules and documentation needs.

Full catalog
Repair and regenerative research

BPC-157

Synthetic gastric pentadecapeptide research reference · preclinical evidence predominates

Purity
Target ≥ 99.0% · Batch COA
CAS
137525-51-0
Latest batch COA available on request
Repair and regenerative research

TB-500

N-acetylated LKKTETQ thymosin-β4 fragment research reference

Purity
Lot-specific · Batch COA
CAS
885340-08-9
Latest batch COA available on request
Immune signaling research

KPV

Lys-Pro-Val α-MSH C-terminal tripeptide

Purity
Target ≥ 99.0% · Batch COA
CAS
67727-97-3
Latest batch COA available on request
Repair and regenerative research

TB500 Fragment (Frag 17-23)

N-acetylated thymosin-β4 residues 17–23 research fragment · not full-length thymosin-β4

Purity
Lot-specific · Batch COA
CAS
885340-08-9
Latest batch COA available on request